Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:completedIn |
2021
|
| gptkbp:designer |
double-blind
placebo-controlled randomized |
| gptkbp:endPoint |
speech perception improvement
|
| gptkbp:enrollment |
95
|
| https://www.w3.org/2000/01/rdf-schema#label |
FX-322 Phase 2a
|
| gptkbp:indication |
sensorineural hearing loss
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:period |
Phase 2a
|
| gptkbp:sponsor |
gptkb:Frequency_Therapeutics
|
| gptkbp:startDate |
2019
|
| gptkbp:studies |
gptkb:FX-322
|
| gptkbp:bfsParent |
gptkb:Frequency_Therapeutics
|
| gptkbp:bfsLayer |
4
|